Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
50,637,251
-
Shares change
-
+795,232
-
Total reported value, excl. options
-
$2,201,420,429
-
Value change
-
-$8,455,097
-
Put/Call ratio
-
116%
-
Number of buys
-
79
-
Number of sells
-
-84
-
Price
-
$43.48
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2018
198 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2018.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50,637,251 shares
of 95,963,102 outstanding shares and own 53% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5,996,082 shares), Capital Research Global Investors (5,856,155 shares), Capital International Investors (4,589,854 shares), BlackRock Inc. (4,476,812 shares), Vanguard Group Inc (4,161,780 shares), FMR LLC (2,946,924 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,730,381 shares), STATE STREET CORP (2,051,639 shares), Capital World Investors (1,583,390 shares), and FIRST TRUST ADVISORS LP (1,471,934 shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.